Company intelligence / Profile preview
OMEICOS Therapeutics
Berlin, Berlin, Germanyomeicos.com ↗
- Ownership
- Private
- Employees
- ~9
- Development stage
- Other
01
Overview
OMEICOS’ lead compound, OMT‑28, has demonstrated an excellent safety and tolerability profile in both healthy volunteers and patients with atrial fibrillation. Phase II studies have shown significant positive effects on inflammatory biomarkers such as GDF‑15 and IL‑6. The ongoing PMD‑OPTION Phase II study in Primary Mitochondrial Disease patients has met enrollment targets; initial data confirm strong safety/tolerability and promising efficacy signals for relevant endpoints. Preclinical work supports expansion into ophthalmology.[1][2][3][6]
- Therapeutic areas
- Rare DiseasesOphthalmologyImmunologyCardiovascular
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
03
Partnerships
Forbion led Series C financing roundREMIGES Ventures participated in Series BGerman Federal Ministry of Education and Research funding for PMD program[2][4][6].
Beyond the preview
Go deeper on OMEICOS Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OMEICOS Therapeutics.